Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Phase Bioscience is a biotechnology firm that has developed a technology utilizing genetically-engineered biopolymer peptides (ELPs) that changes solubility (from a liquid to a solid and back) based on the temperature and the salt content of the solution. Known as deltaPhase, Phase Bioscience's ELPs are designed to be used by pharmaceutical researchers in drug discovery processes and in life science applications, including recombinant protein purification (isolating a particular protein in a solution) and enzyme biocatalysts (isolating a particular recombinant enzyme in a solution).

BioSante Pharmaceuticals, Inc. company was founded in 1996 and is based in Lincolnshire, Illinois. BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. It develops calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. The company's products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Intarcia Therapeutics (formerly BioMedicines) sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or can be effective in treating different indications. Lead drug candidate Atamestane, acquired from Schering AG (now Bayer Schering ), is in clinical trials as a potential treatment for metastatic breast cancer. The company's pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis C; and Biomed 101 (from G.D. Searle), which may have applications for melanoma and kidney cancer.

Astellas Pharma Europe Ltd. is the European subsidiary of Astellas. Astellas Europe employs approximately 3,200 people in Europe and South Africa across Sales and Marketing, Research & Development (R&D), and Manufacturing. Astellas Europe has 20 Sales and Marketing affiliates, three Manufacturing plants, and one R&D centre. Astellas Europe, through Astellas Pharma International, is also responsible for the distribution of the company's products in multiple markets in the Middle East and Africa. Astellas Europe is headquartered just outside London in Staines.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

ImaRx Therapeutics, Inc. company was founded in 1999. ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The MRX-801 microspheres are a proprietary formulation of a lipid shell encapsulating an inert biocompatible gas. Discontinued operations In September 2008, the company divested its urokinase business to Microbix.

Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.